Overview
- Compass Pathways led psychedelic drug stocks higher Monday after President Trump's executive order told HHS, the FDA, and the VA to accelerate research and expand patient access.
- The stock rose about 25% before the open and was up roughly 49% to $9.93 intraday, a new 52-week high, according to Benzinga Pro.
- The company recently posted positive Phase 3 results for COMP360, a synthetic psilocybin for treatment‑resistant depression, and began a rolling FDA submission that lets regulators review sections as they are filed.
- Gains spread across peers as Atai, Definium Therapeutics, GH Research, and Cybin logged double‑digit moves in early trading, with Oppenheimer, Jefferies, and RBC calling the policy a sector inflection.
- Benzinga reported the administration committed $50 million to ibogaine research, while analysts warned that labeling decisions, insurance coverage, clinic capacity, and company financing will determine how fast patients gain access.